Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene

Contemporary Clinical Trials

Volumn 26, Issue 6, 2005, Pages 612-615

  Wenger, Nanette K ^a,b,c   Geiger, Mary Jane ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GRADY MEMORIAL HOSPITAL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Cardiovascular outcome clinical trials; Coronary heart disease; Menopausal hormone therapy; Menopausal women; Raloxifene

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTRADIOL; ESTRADIOL VALERATE; MEDROXYPROGESTERONE ACETATE; RALOXIFENE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENOPAUSE; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; CORONARY DISEASE; DIABETES MELLITUS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MENOPAUSE; MIDDLE AGED; PATIENT SELECTION; RALOXIFENE; RISK FACTORS; SMOKING;

EID: 28344446007     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2005.09.010     Document Type: Article

References (12)

1. American Heart Association Heart Disease and Stroke Statistics-2005 Update 2005 American Heart Association Dallas, TX
2. N.K. Wenger, E. Barrett-Connor, P. Collins for the RUTH Investigators Baseline characteristics of participants in the raloxifene use for the heart (RUTH) trial Am J Cardiol 90 2002 1204 1210
3. S. Hulley, D. Grady, T. Bush for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
4. D.D. Waters, E.L. Alderman, and J. Hsia Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. A randomized controlled trial JAMA 288 2002 2432 2440
5. H.N. Hodis, W.J. Mack, S.P. Azen for the Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women N Engl J Med 349 2003 535 545
6. The ESPRIT team Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial Lancet 360 2002 2001 2008
7. National Center for Health Statistics, Centers for Disease Control and Prevention website. Available at www.cdd.gov/nchs/products/pubd/hestats/obese/ obse.99.htm.
8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
9. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II) Circulation 89 1994 1329 1445
10. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 157 1997 2413 2446
11. A.V. Chobanian, G.L. Bakris, and H.R. Black The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA 289 2003 2560 2572
12. Mack W, University of Southern California, personal communication, August 2003.